Imviva’s ASGCT presentation highlights encouraging clinical responses in SLE. Among 18 evaluable patients with SLE/lupus nephritis (LN) treated with CTA313, with a median follow-up of six months: 50% ...
Lupus, medically known as Systemic Lupus Erythematosus (SLE), is an autoimmune disease in which the body's immune system ...
The "Systemic Lupus Erythematosus - Global Clinical Trials Review, 2026" has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth analysis of the clinical trials landscape ...
The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...
We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...
Adverse childhood experiences are common in children with systemic lupus erythematosus and are linked to higher odds of ...
At 23, Dieu Thuong has repeatedly faced the line between life and death after being diagnosed with lupus, followed by severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results